NCT06708507 Tissue-resident Immune Cell Subsets in aGVHD
| NCT ID | NCT06708507 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Condition | Acute Graft-versus-Host Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-11-16 |
| Primary Completion | 2025-02-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-11-16 with a primary completion date of 2025-02-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent form; 2. Age 16-65 years old 3. Clinically diagnosed with GVHD for the first time/receiving GVHD treatment. Exclusion Criteria: 1. Have a history of other tumors 2. With poor compliance or mental disorders 3. Infected with HIV and HCV 4. With uncontrolled HBV infection 5. With other autoimmune diseases 6. Those who are judged by the researcher to be unsuitable to participate in this study
Contact & Investigator
Hua Jin
PRINCIPAL INVESTIGATOR
Nanfang Hospital, Southern Medical University
Frequently Asked Questions
Who can join the NCT06708507 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Acute Graft-versus-Host Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06708507 currently recruiting?
Yes, NCT06708507 is actively recruiting participants. Contact the research team at 1224940802@qq.com for enrollment information.
Where is the NCT06708507 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06708507 clinical trial?
NCT06708507 is sponsored by Nanfang Hospital, Southern Medical University. The principal investigator is Hua Jin at Nanfang Hospital, Southern Medical University. The trial plans to enroll 40 participants.